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Abstract
Background: Investigations into both the pathophysiology and therapeutic targets in muscle dystrophies have
been hampered by the limited proliferative capacity of human myoblasts. Isolation of reliable and stable
immortalized cell lines from patient biopsies is a powerful tool for investigating pathological mechanisms,
including those associated with muscle aging, and for developing innovative gene-based, cell-based or
pharmacological biotherapies.
Methods: Using transduction with both telomerase-expressing and cyclin-dependent kinase 4-expressing vectors,
we were able to generate a battery of immortalized human muscle stem-cell lines from patients with various
neuromuscular disorders.
Results: The immortalized human cell lines from patients with Duchenne muscular dystrophy, facioscapulohumeral
muscular dystrophy, oculopharyngeal muscular dystrophy, congenital muscular dystrophy, and limb-girdle muscular
dystrophy type 2B had greatly increased proliferative capacity, and maintained their potential to differentiate both
in vitro and in vivo after transplantation into regenerating muscle of immunodeficient mice.
Conclusions: Dystrophic cellular models are required as a supplement to animal models to assess cellular
mechanisms, such as signaling defects, or to perform high-throughput screening for therapeutic molecules. These
investigations have been conducted for many years on cells derived from animals, and would greatly benefit from
having human cell models with prolonged proliferative capacity. Furthermore, the possibility to assess in vivo the
regenerative capacity of these cells extends their potential use. The innovative cellular tools derived from several
different neuromuscular diseases as described in this report will allow investigation of the pathophysiology of
these disorders and assessment of new therapeutic strategies.
Background
Muscular dystrophies constitute a heterogeneous group
of genetic muscle diseases characterized by progressive
muscle weakness, wasting and degeneration, some of
these features are common to muscle aging [1,2]. Over
the past few years, the genetics and pathophysiology of
some of these diseases has been deciphered, stimulating
the development of novel gene-based (or mRNA-based)
(for example, gene therapy, exon-skipping or codon
read-through), cell-based and pharmacological therapies
[3], which can either target the mutation directly, or tar-
get the consequences of that mutation, such as muscle
wasting, atrophy or denervation. To assess these rapidly
developing therapeutic advances, there is a crucial need
to develop standardized tools to determine the cellular
and molecular mechanisms that trigger the physiopatho-
logic modifications, and to assess these new therapeutic
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often been used to investigate the physiopathology of
muscular dystrophies [4-6]; however, the mutation
remains in a murine context, and there are often major
differences between humans and mice; for example, a
mutation in the dystrophin gene results in a mild patho-
logical phenotype in mdx mice but in a progressive and
fatal disease (Duchenne muscular dystrophy; DMD) in
humans. Furthermore, not every mutation can be cre-
ated and evaluated in murine models, and mechanisms
common to aging and dystrophies may differ between
mice and humans. Consequently, human primary myo-
blasts isolated from dystrophic patient biopsies provide
the most pertinent experimental models to assess a vari-
ety of human genetic mutations in their natural genomic
environment. Although in vitro models do not fully
recapitulate the in vivo environment, cell-culture sys-
tems allow rapid, high-throughput screening of mole-
cules or oligonucleotides, and new strategies can be
easily tested prior to validation in animal models, which
is a costly and time-consuming process. The main draw-
backs of using in vitro primary cultures of human cells
derived from muscle biopsies are their purity, their lim-
ited proliferative capacity, and the variation in pheno-
type when amplified in vitro; their phenotype will always
be confounded by modifications due to cellular senes-
cence, which will progressively occur during cell amplifi-
cation [7,8].
The two major mechanisms responsible for this
replicative cellular senescence seen in human myo-
blasts are (i) activation of the p16-mediated cellular
stress pathway, and (ii) the progressive erosion of telo-
meres at each cell division until they reach a critical
length that will trigger p53 activation and cell-cycle
exit [9,10]. Introduction of the telomerase catalytic
subunit (human telomerase reverse transcriptase;
hTERT) cDNA alone will result in an extension of the
lifespan and even immortalization in a variety of cell
types, including endothelial cells and fibroblasts
[11,12]. However, we have shown that the expression
of both hTERT and cyclin-dependent kinase (CDK)-4 is
required to successfully overcome cellular senescence
in human myoblasts [13]; while hTERT elongates the
telomere, CDK-4 blocks the p16
INK4a-dependent stress
pathway.
In the present study, our goal was to create a large
collection of immortalized human myoblastsi s o l a t e d
from a wide range of neuromuscular disorders (DMD,
facioscapulohumeral muscular dystrophy (FSHD), oculo-
pharyngeal muscular dystrophy (OPMD), limb-girdle
muscular dystrophy (LGMD2B or dysferlinopathy) and
congenital muscular dystrophy (CMD)), which could be
used as experimental tools to study these diseases and
to develop new therapeutic strategies.
DMD is the most common childhood muscular dys-
trophy. It is caused by mutations in the dystrophin gene
encoding an essential protein of the muscle membrane
cytoskeleton [14], leading to rapid and progressive skele-
tal-muscle weakness. FSHD is a progressive muscle dis-
ease caused by contractions in a 3.3 kb repeat region
(D4Z4) located at 4q35.2 [15], which first affects the
muscles of the face and upper limb girdle with asymme-
try, and later the lower limb girdle. OPMD is a rare,
autosomal dominant, late-onset degenerative muscle dis-
order caused by a short (GCG)n triplet expansion in the
poly(A) binding protein nuclear 1 (PABPN1)g e n e[ 1 6 ] ,
which affects the eyelid and pharyngeal muscles.
LGMD2B is a recessive muscle disease caused by muta-
tions in the dysferlin gene, a muscle membrane protein
known to be involved in membrane repair [17] and traf-
ficking. The disease is characterized by early and slowly
progressive weakness and atrophy of the pelvic and
shoulder girdle muscles in early adulthood. Finally,
CMD refers to a clinically and genetically heterogeneous
group of dystrophies, which result in the onset of mus-
cle weakness at birth or in childhood, and involve muta-
tions in several proteins such as collagen, laminin,
integrin, and nesprin 1 [18].
In this study, we report for the first time that for each
o ft h e s em u s c u l a rd y s t r o p h i e s ,w ew e r ea b l et op r o d u c e
reliable and stable immortalized cell lines from human
myoblasts isolated from biopsies, resulting in robust in
vitro models that can also be implanted in vivo.T h i s
non-exhaustive list of cellular models will provide
powerful and valuable tools for the scientific community
investigating these pathological conditions and/or their
mechanisms. as they overcome the problem of limited
proliferation usually present in myoblasts. These models
should also be useful in the development of gene or cell
therapies and pharmacological strategies for muscular
dystrophies, some of which might also be used to com-
bat muscle weakness in the elderly.
Methods
Ethics approval
Muscle biopsies (Table 1) were obtained from the BTR
(Bank of Tissues for Research, a partner in the EU net-
work EuroBioBank) or from neurologists, in accordance
with European recommendations and French legislation.
Surgical procedures were performed in accordance with
the legal regulations in France and European Union
ethics guidelines for animal research.
Human myoblast cultures
Human myoblasts were isolated from biopsies and culti-
vated as described previously [19] in a growth medium
consisting of 199 medium and DMEM (Invitrogen
Carlsbad, CA) in a 1:4 ratio, supplemented with 20%
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Page 2 of 10FCS (Invitrogen), 2.5 ng/ml hepatocyte growth factor
(Invitrogen), 0.1 μmol/l dexamethasone (Sigma-Aldrich,
St. Louis, MO, USA) and 50 μg/ml gentamycin (Invitro-
gen). The myogenic purity of the populations was moni-
tored by immunocytochemistry using desmin as marker.
Enrichment of myogenic cells was performed using an
immunomagnetic cell sorting system (MACS; Miltenyi
Biotec, Paris, France) according to the manufacturer’s
instructions. Briefly, cells were labeled with anti-CD56
(a specific marker of myoblasts) microbeads, and then
separated in a MACS column placed in a magnetic field.
Purification was checked by immunochemistry using a
desmin marker. Differentiation was induced at conflu-
ence by replacing the growth medium with DMEM sup-
plemented with 100 μg/ml transferrin, 10 μg/ml insulin
and 50 μg/ml of gentamycin (Sigma-Aldrich).
Cell transduction
hTERT and Cdk4 cDNA were cloned into different
pBABE retroviral vectors containing puromycin and
neomycin selection markers, respectively. Infection was
carried out as described previously [20]. Transduced cell
cultures were selected with puromycin (0.2 μg/ml) and/
or neomycin (0.3 mg/ml) for 8 days. The infected cells
were purified as described previously if necessary, and
were then seeded at clonal density. Selected individual
myogenic clones were isolated from each population,
using glass cylinders, and their proliferation and differ-
entiation capacities were characterized.
Telomere length analysis
Genomic DNA was extracted from each proliferating
cell line using a salting-out procedure. Telomere length
was determined by using a quantitative (q)PCR method,
as previously described [21,22]. PCR amplification was
achieved using telomere (T) and single-copy gene 36B4
(acidic ribosomal phosphoprotein P0) (S) primers. The
mean telomere length was calculated as the ratio of telo-
mere repeats to 36B4 copies, represented as the T:S
ratio. Each sample was run in triplicate, using 20 ng of
DNA per replicate, and three independent runs were
analyzed. The primer sequences and detailed PCR pro-
tocols used are available on request.
Reverse transcriptase PCR
To analyze the expression of myogenic markers in pro-
liferating primary and immortalized cell lines, 1 μg RNA
from each cell line was used for the cDNA synthesis
(Superscript III; Invitrogen) using random hexamer pri-
mers. cDNA (1 μl) was used as a template for PCR
using N-CAM, MyoD and desmin specific primers. The
primer sequences and detailed PCR protocols used are
available on request.
Induction of host muscle regeneration and implantation
of human cells
Immunodeficient Rag2
-/- gC
-/- C5
-/- mice aged 2 to 3
months were anesthetized with an intraperitoneal injec-
tion of ketamine hydrochloride (80 mg/kg) and xylasin
(10 mg/kg) (Sigma-Aldrich). To induce severe muscle
damage and trigger regeneration, the recipient tibialis
anterior (TA) muscles were exposed to cryodamage, and
a single injection of immortalized human cells (15 μlo f
cell suspension containing 2.5 × 10
5 or 5 × 10
5 cells in
PBS) was administered as described previously [23].
Four weeks after transplantation, the recipient TA mus-
cles were dissected, mounted in gum tragacanth, and
frozen in liquid nitrogen-cooled isopentane for later
analysis.
Immunofluorescence
In vitro and in vivo characterizations were performed by
immunolabeling as described previously [23-25]. Antibo-
dies used were directed against myosin isoforms (MF20,
mouse IgG2b, 1:20 dilution; Developmental Studies
Hybridoma Bank, DSHB, Iowa City, IA), lamin A/C
(clone JOL2, mouse IgG1, 1:300; AbCam, Cambridge,
Cambridgeshire, UK), lamin A/C (NCL-LAM A/C, clone
636, mouse IgG2b, 1:400, Novocastra, Newcastle-upon-
Tyne, Tyne and Wear, UK), spectrin (NCL-Spec1, clone
RBC2/3D5, mouse IgG2b, 1:50; Novocastra), and lami-
nin (rabbit polyclonal, Z 0097, 1:400; Dako, Trappes,
France). The secondary antibodies used were Alexa
Fluor 488-conjugated goat anti-mouse IgG2b (Molecular
Probes, Montluçon, France), Alexa Fluor 647-conjugated
goat anti-rabbit (Molecular Probes), and Cy3-conjugated
goat anti-mouse IgG1 (Jackson Immunoresearch, West
Table 1 Muscle biopsies obtained from various neuromuscular dystrophies.
Name Disease Genetic defect Donor muscle Age
CTRL None None Semitendinosus 25 years
CMD Congenital muscular dystrophy 2345G > T; nesprin-1 gene Paravetrebral 16 years
DMD Duchenne muscular dystrophy Deletion of exon 48-50; dystrophin gene Quadriceps 20 months
FSHD Fascioscapulohumeral muscular dystrophy 2 D4Z4 contraction Subscapularis 27 years
LGMD2B Limb-girdle muscular dystrophy type 2B 1448C > A and 107T > A; dysferlin gene Quadriceps 40 years
OPMD Oculopharyngeal muscular dystrophy Expansion (GCG)9-(GCG)6; PABPN1 gene Cricopharyngeal 60 years
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scope (Olympus Corp., Tokyo, Japan), and digitized
using a charge-coupled device (CCD) camera (Olympus
Corp., Tokyo, Japan).
Antisense oligonucleotides transfection and reverse
transcriptase PCR
Cells were seeded in six-well plates and grown in
growth medium. Transfection of antisense oligonucleo-
tides (AONs) was performed using 1 μl of transfection
reagent (Lipofectamin 2000; Invitrogen) per μg of AONs
for 4 hours. The chemistry used for AONs was 2’-O-
methyl-phosphorothioates. All transfections were per-
formed with at least two independent duplicates. Cells
were changed to differentiation medium before transfec-
tion. Typically 24 to 48 hours after transfection, RNA
was extracted from the cells using Trizol or Qiagen col-
umn kit (Qiagen Inc., Valencia, CA, USA). 1 μgR N A
was used for the cDNA synthesis (Superscript III; Invi-
trogen) with DMD exon-specific primers. cDNA (2 μl)
was used as a template for a first PCR reaction. From
this first reaction of 25 cycles, 1 μl of the product was
removed and used as a template for a second nested
PCR of 35 cycles. PCR products were analyzed on 1.5 to
2% agarose gels. The primer sequences and detailed
PCR protocols used are available on request.
Results
Immortalized myoblast lines generated from dystrophic
muscles
Primary cultures from distinct muscular dystrophies
(DMD, FSHD, OPMD, CMD and LGMD2B, Table 1)
were co-transduced with two retroviral vectors expres-
sing hTERT and CDK-4 cDNA. Co-transduced cells
were selected by neomycin and puromycin and then
purified using magnetic beads coupled to antibodies
directed against the myogenic marker CD56. Following
culture at clonal density, individual myogenic clones
with extended proliferative lifespans, as compared to the
untranduced cells, were isolated from each population.
In contrast to the parental populations, which stopped
proliferating at various stages of the culture, depending
on the type of dystrophy, the selected immortalized
clones were still able to proliferate after prolonged
amplification in vitro under the same culture conditions
(Figure 1). All immortalized clones were cultivated until
they had achieved at least twice as many divisions as the
parental population.
Telomere length was measured in each clone (Table
2) and ranged from 10.3 kb to 24.8 kb with no differ-
ence between the clones and control immortalized myo-
blasts (17.6 kb). The length of the telomeres in all of the
immortalized myogenic clones was always well above
the 6 to 7 kb limit usually seen in control cells that are
reaching senescence, but remained within the range of
that seen both in myoblasts and in other stem cells (12
to 20 kb).
In vitro characterization of immortalized cells
To confirm that the immortalized cell lines maintained
their myogenic signature, we compared the expression
of several markers in proliferating primary and immor-
talized cell lines from control, OPMD and DMD biop-
sies. In all of them, we confirmed the expression of the
myogenic markers desmin, neural cell adhesion mole-
cule (N-CAM) and MyoD (Figure 2A).
In addition, we also tested their ability to differentiate
into myotubes, using immunostaining with MF20 anti-
body, which recognizes all skeletal-muscle myosin heavy
chains (MyHCs). After 5 days in differentiation condi-
tions, all of the immortalized cell lines were able to fuse
into myotubes expressing MyHCs (Figure 2B).
Induction of host muscle regeneration and implantation
of human cells
To investigate the in vivo behavior of these immorta-
lized cells, cells were grafted into damaged TA muscles
of Rag2
-/- gC
-/- C5
-/- mice; injected muscles were ana-
lyzed 4 weeks after transplantation, which corresponds
to a complete fiber regeneration process, using antibo-
dies specific for human lamin A/C (expressed in all
human nuclei) and human spectrin (expressed in differ-
entiated fibers). For each injected clone (control, DMD,
FSHD, OPMD, CMD or LGMD2B), mature muscle
fibers containing human spectrin protein and human
lamin A/C+ nuclei were seen (Figure 3A). No tumors
were ever observed in these immunodeficient mice.
Using antibodies specific for the basal lamina protein
laminin, lamin A/C (human nuclei) and spectrin (speci-
fic to the human protein) to identify fiber sarcolemma,
we investigated if these cell lines could replenish the
muscle stem-cell niche (allowing self-renewal), at the
periphery of the muscle fiber and beneath the basal
lamina. Whereas the vast majority of the lamin A/C-
positive nuclei (97%) were found as myonuclei (upper
panel, Figure 3B), we observed the unexpected finding
that all the human cells outside the muscle fibers were
present in the interstitial space, separated from the
fibers by a basal lamina (lower panel, Figure 3B), and
not in the satellite-cell niche, suggesting that the
immortalized cells were engaged preferentially in the
differentiation pathway and not in the self-renewal
process.
Immortalized cell lines as a useful tool for therapeutic
preclinical studies
To show that these cell lines could be powerful tools to
develop therapeutic strategies, we used them to evaluate
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DMD. The first one tested was AO51, which resulted in
efficient skipping of exon 51 using both the primary and
immortalized DMD cell lines (Δ48 to 50; Figure 4A)
and this AON is currently being used in a phase I/II
clinical trial. Using immortalized control cells, we were
able to screen a range of AONs targeting exons 17, 18,
21, 22, 43, 44 and 45 of the dystrophin gene. RT-PCR
Figure 1 Proliferative potential. Lifespan plots (mean population doublings; MPD) of the parental populations and the immortalized cell lines
derived from them.
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and data not shown).
Discussion
Immortal human cell lines, as long as they retain their
capacity to express a specific program, are essential to
study cellular and molecular mechanisms (as exempli-
fied by the number of studies conducted on the mouse
cell line C2C12), and responses to potential therapeutic
strategies. The relatively short proliferative lifespan of
human myoblasts, reduced even more in dystrophic
conditions by successive cycles of degeneration/regen-
eration in vivo prior to isolation and the modification in
their myogenic potential as they approach senescence
[26-28], limits their potential use. As a consequence,
any assessment of pathological mechanisms or of thera-
peutic strategies will be biased by the presence of senes-
cent cells, which will modify the behavior of the
population. This is even more crucial for high-through-
put screening of molecules, for which large numbers of
cells are required. Immortalization can solve this pro-
blem, as long as the cell lines are stable and retain most
of the characteristics of the unmodified parental popula-
tion. This has been shown to be a problem with the
C2C12 cell line, as the phenotype drifts and therefore
can vary both within and between different laboratories.
Immortal cell lines have been generated from human
skeletal muscle, such as those derived from rhabdomyo-
sarcomas, a rare form of skeletal-muscle tumor. How-
ever, these lines often have impaired fusion
characteristics and perturbed myogenic programs
[29,30]. Other approaches have used transduction of the
large T antigen from SV40, which binds Rb and p53,
but does not stop telomere shortening. Although these
cells do have an extended lifespan, they are not immor-
tal, and extensive telomeric erosion results in an
increased frequency of chromosomal rearrangement [31]
and a defective differentiation program [32]. More
recently, cell lines were generated by the transduction of
primary myoblasts with both hTERT and Bmi-1, which
downregulates both the p16 and p19Arf tumor suppres-
sor genes, encoded by the Ink4 locus. These cells had
an extended lifespan with no chromosomal rearrange-
ment, but the differentiation potential of control myo-
blasts was found to be impaired [33]. This year, a report
described the same approach as we have used in the
present study (introduction of hTERT and CDK4) using
muscle cells isolated from patients affected with FSHD
[34]. The FSHD mutation causes a defect within myo-
genic cells, thus the establishment of a clonal myogenic
cell line permit reproducible study of the consequences
Table 2 Mean telomere length of control and
immortalized cell lines.
Name Clone Number of
divisions
Telomere length, kb, mean
± SEM
CTRL C25Cl48 127 17.6 ± 0.3
CMD CMDCl12 42 20.8 ± 1.7
DMD DMDCl2 57.9 10.3 ± 0.1
FSHD FSHDCl17 37.9 24.8 ± 1.6
LGMD2B LGMD2Cl11 27.4 17.2 ± 3.0
OPMD OPMDCl2 47.6 20.0 ± 0.5
CMD, congenital muscular dystrophy; DMD, Duchenne muscular dystrophy;
FSHD, fascioscapulohumeral muscular dystrophy; LGMD2B, limb-girdle
muscular dystrophy type 2B; OPMD, oculopharyngeal muscular dystrophy
Figure 2 Myogenic markers and in vitro differentiation. (A)
Reverse transcriptase PCR comparing primary (P) and immortalized
(Im.) cell lines (control, oculopharyngeal muscular dystrophy
(OPMD), Duchenne muscular dystrophy (DMD)) for myogenic
markers (MyoD, N-CAM and desmin). Fibroblasts were used as a
negative control. (B) Immunofluorescence was carried out using
MF20, an antibody directed against sarcomeric myosin (green) after
5 days of differentiation. Specific antibody labeling was visualized
using Alexa Fluor 488 secondary antibody (green). Nuclei were
visualized with Hoechst (blue). Original magnification × 100.
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nation of non-myogenic cells. The decrease in myogeni-
city in the primary culture, and consequently the
enrichment of non-myogenic cells during amplification,
is a considerable problem in the study of dystrophy dis-
eases. For example, in 2006, we described rapid loss of
myogenicity during successive passages of primary cul-
tures of muscle cells isolated from patients with OPMD
[35]; many muscle diseases are subject to a similar
decrease in myogenicity. In this report, we describe the
isolation of immortalized human myoblast lines from a
wide range of neuromuscular diseases, using a combina-
tion of hTERT and CDK-4. This wide range of diseases
paves the way to searching for common mechanisms
between distinct dystrophies, and even those shared
with muscle aging, as opposed to those mechanisms
specific for each disease. We found that these cell lines
have extended proliferative lifespans, and maintain their
capacity to differentiate both in vitro and in vivo after
transplantation into the regenerating muscles of immu-
nodeficient mice. We found that these human myoblast
cell lines expressing myogenic markers could colonize
the host muscles and form mature fibers, thus providing
an ideal model to assess therapeutic strategies in vivo,
which is closer to bona fide differentiation of muscle
stem cells than the converted fibroblasts described pre-
viously [36]. We also found that these cells do not
replenish the muscle stem-cell niche as primary human
myoblasts do under the same conditions of implantation
[23], but are engaged primarily in the differentiation
pathway. The process of immortalization involves over-
expression of both hTERT and CDK-4, and further
investigations will be needed to analyze how this may
influence the balance between self-renewal and
differentiation.
Conclusions
These human myoblast lines represent a powerful tool
to assess signaling and/or functional deregulations in
neuromuscular diseases, particularly those in which
these mechanisms have not yet been clearly elucidated
(FSHD, OPMD) or those with features common to mus-
cle aging, such as atrophy or muscle wasting. We have
described only a subset of the cell lines produced; we
have now generated more than 35 cell lines with various
mutations covering a range of 14 different pathologies,
as well as cell lines from control subjects of various
ages. The in vivo implantation of these cells offers the
possibility to investigate the consequences of defined
mutations on cellular behavior in vivo, particularly with
regard to their regenerative capacity. Finally, the devel-
opment of therapeutic strategies, whether these strate-
gies imply gene, cell or pharmacological therapy
involving high-throughput screening, is facilitated using
these tools before assessment in animal models. As an
example, we have described a rapid screen of a range of
AONs in an exon-skipping strategy for DMD. In conclu-
sion, the co-transduction of hTERT and CDK4
Figure 3 Detection of human immortalized cells injected into
in the tibialis anterior muscle of Rag2
-/- gC
-/- C5
-/- mice. (A)
Human nuclei were visualized using an anti-lamin A/C antibody
(red) and fibers expressing human proteins were visualized using an
anti-human spectrin-specific antibody (green). Nuclei are
counterstained with Hoechst. Original magnification × 200. (B) The
immortalized cells were present preferentially as myonuclei (top
panel), with a small number found in interstitial space (arrow,
bottom panel), identified by human lamin expression (laminin
staining in green, laminA/C and spectrin staining in red, Hoechst in
blue, on the LGMD2B muscle section as an example). Original
magnification × 600.
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maintain myogenic potential both in vitro and in vivo,
offering new cell paradigms for pathophysiological stu-
dies and novel therapeutic strategies.
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